Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia

Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with ... Biopharmaceuticals Alkermes, ALPINE study, ARISTADA, INVEGA SUSTENN, schizophrenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news